scholarly journals Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC‐4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers

2016 ◽  
Vol 5 (10) ◽  
pp. 532-543 ◽  
Author(s):  
HY Choi ◽  
S Choi ◽  
YH Kim ◽  
HS Lim
Keyword(s):  
Healthy Volunteers ◽  
Factor Xa ◽  
Pharmacodynamic Modeling ◽  
Population Pharmacokinetic ◽  
Factor Xa Inhibitor ◽  
Direct Factor ◽  
Modeling Analysis

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

2011 ◽  
Vol 51 (5) ◽  
pp. 687-694 ◽  
Author(s):  
Jeanne Mendell ◽  
Masaya Tachibana ◽  
Minggao Shi ◽  
Satoshi Kunitada
Keyword(s):  
Healthy Volunteers ◽  
Factor Xa ◽  
Factor Xa Inhibitor ◽  
Direct Factor

Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers

2005 ◽  
Vol 93 (04) ◽  
pp. 794-795 ◽  
Author(s):  
Anne Paccaly ◽  
Annke Frick ◽  
Umesh Shukla ◽  
Kelly Simcox ◽  
Barry Miller ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Factor Xa ◽  
Factor Xa Inhibitor ◽  
Direct Factor

Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans

2012 ◽  
Vol 40 (12) ◽  
pp. 2250-2255 ◽  
Author(s):  
Mohinder S. Bathala ◽  
Hiroshi Masumoto ◽  
Toshihiro Oguma ◽  
Ling He ◽  
Chris Lowrie ◽  
...  
Keyword(s):  
Mass Balance ◽  
Factor Xa ◽  
Factor Xa Inhibitor ◽  
Direct Factor

Betrixaban – the next direct factor Xa inhibitor?

2016 ◽  
Vol 9 (12) ◽  
pp. 1111-1117 ◽  
Author(s):  
Martin Thoenes ◽  
Joan Minguet ◽  
Karin Bramlage ◽  
Peter Bramlage ◽  
Carmen Ferrero
Keyword(s):  
Factor Xa ◽  
Factor Xa Inhibitor ◽  
Direct Factor

scholarly journals In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor

2005 ◽  
Vol 3 (3) ◽  
pp. 514-521 ◽  
Author(s):  
E. PERZBORN ◽  
J. STRASSBURGER ◽  
A. WILMEN ◽  
J. POHLMANN ◽  
S. ROEHRIG ◽  
...  
Keyword(s):  
Factor Xa ◽  
In Vivo Studies ◽  
Factor Xa Inhibitor ◽  
The Novel ◽  
Direct Factor ◽  
Antithrombotic Agent

Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients

2018 ◽  
Vol 35 (9) ◽  
pp. 903-908 ◽  
Author(s):  
Teresa A. Allison ◽  
Pei Jen Lin ◽  
Jennifer A. Gass ◽  
Kenneth Chong ◽  
Samuel J. Prater ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Prothrombin Complex Concentrate ◽  
Low Dose ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Factor Xa ◽  
Final Analysis ◽  
Factor Xa Inhibitor ◽  
Direct Factor

Objective: This study investigated the percentage of patients who achieved hemostasis with 4-factor prothrombin complex concentrate (4-factor PCC) 35 U/kg. The primary end point was to determine the effect of 4-factor PCC 35 U/kg on bleeding progression, assessed using computed tomography. Methods: This was a retrospective, observational, single-center study conducted in patients with a major bleed admitted to a level 1 trauma center from May 1, 2013, to June 15, 2015, who received 4-factor PCC 35 U/kg for reversal of a direct factor Xa inhibitor taken prior to admission. Results: Thirty-three patients were included in the study, with 31 patients in the final analysis. The mean (standard deviation) age was 73 (14.8) years; 54.5% of patients were female. Of the 33 patients, 13 presented with a traumatic brain injury, 9 with an aneurysmal subarachnoid hemorrhage, 8 with an intracerebral hemorrhage, 1 with a gastrointestinal bleed, 1 with a hematoma with active extravasation, and 1 with an intra-abdominal bleed. The most frequently used direct factor Xa inhibitor was rivaroxaban (81.8%). Overall, 83.8% of patients achieved hemostasis with 4-factor PCC 35 U/kg. Progression of hemorrhage was observed in 4 patients on repeat computed tomography scan and 1 patient had continued surgical bleeding. No thromboembolic events were reported. Conclusions: Low-dose, 4-factor PCC 35 U/kg appeared to produce hemostasis in a majority of the patients. This may be an effective dosing regimen for anticoagulant reversal of factor Xa inhibitors in clinically bleeding patients.

scholarly journals Identification of ssDNA specific to a direct factor Xa inhibitor

2020 ◽  
Author(s):  
Ka Lok Hong ◽  
Nevina Trunzo ◽  
Mina Roueinfar ◽  
Kiersten B. Wiedwald ◽  
Julia Iskra ◽  
...  
Keyword(s):  
Factor Xa ◽  
Factor Xa Inhibitor ◽  
Direct Factor

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

2010 ◽  
Vol 50 (7) ◽  
pp. 743-753 ◽  
Author(s):  
Koichiro Ogata ◽  
Jeanne Mendell-Harary ◽  
Masaya Tachibana ◽  
Hiroshi Masumoto ◽  
Toshihiro Oguma ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Factor Xa ◽  
Factor Xa Inhibitor ◽  
The Novel ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Clinical Safety
Sign in / Sign up

Export Citation Format

Share Document